| Chr | NA |
| start | NA |
| end | NA |
| lncRNA name | PAX8-AS1-N |
| entrez id | NA |
| hgnc id | NA |
| ensg id | NA |
| refseq id | NA |
| methods | qPCR, Western blot etc. |
| regulated | down-regulated |
| function description | we identified a novel isoform of lncRNA PAX8-AS1 (PAX8-AS1-N), which is activated by baicalein in a dose- and time-dependent manner.PAX8-AS1-N reduced cell viability,inhibited cell-cycle progression,and induced apoptosis of breast cancer cells in vitro.Depletion of PAX8-AS1-N promoted breast xenograft tumor growth in vivo. Furthermore, depletion of PAX8-AS1-N attenuated the suppressive roles of baicalein on cell viability,the apoptosis induced by baicalein, and also the suppressive roles of baicalein on tumor growth in vivo. Mechanistically, PAX8-AS1-N bound to miR-17-5p, and up-regulated miR-17-5p targets,such as PTEN, CDKN1A, and ZBTB4. In addition, PAX8-AS1-N was down-regulated in breast cancer and reduced expression of PAX8-AS1-N indicated poor survival of breast cancer patients. |
| pubmed id | 29693272 |
| year | 2018 |
| title | Baicalein inhibits breast cancer growth via activating a novel isoform of the long noncoding RNA PAX8-AS1-N. |
| drug | X |
| circulating | X |
| survival | V |
CopyRight © University of Miami, USA; Harbin Medical University, China